Lenalidomide after Stem-Cell Transplantation for Multiple MyelomaPhilip L. McCarthy, Charles Linker, Daniel J. Weisdorf et al.|New England Journal of Medicine|2012Cited by 1.1k
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple MyelomaPaula Rodríguez‐Otero, Sergio Giralt, Sikander Ailawadhi et al.|New England Journal of Medicine|2023Cited by 695
Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.Sagar Lonial, Monique C. Minnema, Sebastian Grosicki et al.|Journal of Clinical Oncology|2022Cited by 25
OAB-052: Impact of chromosome 1 abnormalities on newly diagnosed multiple myeloma treated with proteasome inhibitor, immunomodulatory drug, and dexamethasone: analysis from the ENDURANCE ECOG-ACRIN E1A11 trialPrashant Kapoor, Shaji Kumar, Timothy M. Schmidt et al.|Clinical Lymphoma Myeloma & Leukemia|2021Cited by 16